[Potential strategies for managing chronic nonspecific lower back pain with the fixed-dose combination Dorsumio]

Lower back pain (LBP) is discomfort localized between the twelfth pair of ribs and the gluteal folds. Chronic LBP, defined as pain persisting for 12 weeks or longer, is a significant global health concern, with a worldwide prevalence of 7.5% in 2017. In a Russian epidemiological study, the lower back was the most frequent site of chronic pain, accounting for 37% of cases. Among pharmacological interventions for LBP, nonsteroidal anti-inflammatory drugs (NSAIDs) and centrally acting muscle relaxants are most commonly used to reduce muscle tension and pain. Of note, 46% of patients with LBP experience depression of varying severity. For patients with chronic LBP, combination therapies incorporating both a muscle relaxant and an antidepressant, such as Dorsumio (comprising 6 mg of tizanidine and 15 mg of mirtazapine), are recommended. Several studies have demonstrated the efficacy and safety of Dorsumio in chronic LBP. The Board of Experts considers Dorsumio a rational option for patients with chronic LBP accompanied by mild to moderate depression.